Rhubarb

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion inflammation weight

Research Overview

Across the provided abstracts, rhubarb (including Rheum species used as foods, supplements, and traditional Chinese medicine preparations) is most frequently studied in relation to gastrointestinal function and chronic kidney disease (CKD), with additional emerging work in neuroprotection via the gut–brain axis and in women’s health as an estrogenic botanical (notably Rheum rhaponticum). Mechanistic research emphasizes rhubarb’s complex phytochemistry (e.g., anthraquinones such as emodin, and other constituents identified by LC–MS/MS) and downstream effects on inflammation, oxidative stress, fibrosis pathways, epithelial barrier integrity, and microbiome/metabolome profiles. The evidence base represented here is largely composed of reviews and preclinical studies (animal models, omics profiling), with rhubarb also appearing in broader clinical-dietary discussions as a “functional food” option for constipation/IBS management.

The strongest support in these abstracts is for biologically plausible, mechanism-linked effects in CKD and in experimental cerebral ischaemia–reperfusion injury (CIRI). For CKD, reviews and metabolomics-oriented animal studies converge on nephroprotective/anti-fibrotic potential, while also highlighting a key safety signal: long-term or inappropriate use may be nephrotoxic, implying a narrow therapeutic window dependent on dose, preparation, and patient factors. For CIRI, an animal MCAO study reports that rhubarb extract improved neurological outcomes alongside microbiome shifts (e.g., reduced Enterobacteriaceae), partial correction of metabolic disturbances, improved intestinal barrier markers (ZO-1, occludin, claudin-1), reduced circulating endotoxin-related markers (LPS, D-lactate), and attenuation of BBB dysfunction and inflammatory signaling (TLR4/MyD88/NF-κB). In contrast, the IBS/functional constipation mention positions rhubarb among several functional foods, but the abstract does not provide direct efficacy estimates, suggesting that clinical evidence in these indications is less developed or not the primary focus of the cited work.

Major gaps include the need for rigorous, well-controlled human clinical trials that standardize rhubarb species, extraction methods, and dosing, and that measure clinically meaningful endpoints (e.g., renal function trajectories in CKD; symptom and stool outcomes in constipation/IBS; neurological outcomes in stroke) alongside safety monitoring. Additional priorities are clarifying which constituents/fractions drive benefit versus toxicity (e.g., anthraquinone-rich fractions), defining pharmacokinetics and herb–drug interaction risks (particularly relevant in CKD and in women using botanicals), and validating proposed mechanisms (microbiome/metabolome changes, barrier repair, anti-inflammatory signaling) in humans. Overall, current research supports promising mechanistic and preclinical signals—especially for CKD-related fibrosis/inflammation and gut–brain axis-mediated neuroprotection—while underscoring that translation to clinical practice requires stronger human evidence and clearer safety/standardization frameworks.

1. What conditions has Rhubarb been studied for?

  • IBS and functional constipation (FC): Mentioned as a “functional food” option discussed alongside other dietary interventions for IBS/FC management (review-level evidence).

  • Chronic kidney disease (CKD): Traditional Chinese medicine use; studied for nephroprotection and anti-fibrotic effects, with attention to both benefits and potential nephrotoxicity (review; plus animal metabolomics study of different extracts).

  • Diabetic nephropathy (DN): Reported clinical effects in patients (reduced proteinuria, lowered blood sugar, improved kidney function) and explored mechanistically using network pharmacology/molecular docking (hypothesis-generating).

  • Cerebral ischaemia-reperfusion injury (CIRI)/stroke model: Rhubarb extract tested in a rat middle cerebral artery occlusion (MCAO) model, focusing on gut-brain axis mechanisms.

  • Menopausal symptoms (women’s health): A specific rhubarb species/extract (Rheum rhaponticum) is listed among botanicals with estrogenic activities used for menopausal symptom relief (broad review; not necessarily rhubarb root used as a laxative).

  • Cancer (preclinical/mechanistic): Aloe-emodin (an anthraquinone from rhubarb) evaluated for hepatocellular carcinoma (HCC) via network pharmacology, docking, and in vitro experiments (abstract truncated but clearly positioned as mechanistic + cell-based).

  • Neurological diseases via resveratrol source: Rhubarb is listed as one dietary source of resveratrol; the abstract focuses on resveratrol’s neuroprotective potential and delivery limitations rather than rhubarb itself.

2. Does it work in treating those conditions? Summarize the evidence.

  • IBS/functional constipation: The IBS/FC dietary review includes rhubarb among “functional foods” discussed for management, but the abstract does not provide trial outcomes, effect sizes, or certainty. From the provided text alone, efficacy cannot be confirmed.

  • CKD (animal + review evidence):

    • A CKD-focused review states rhubarb has “good nephroprotective effect,” with proposed mechanisms including protection from fibrosis, oxidation, inflammation, autophagy, and apoptosis, while also warning that long-term inappropriate use may damage renal function.

    • An adenine-induced CKD rat study found that petroleum ether (PE), ethyl acetate (EA), and n-butanol (BU) rhubarb extracts improved renal function and histopathology (including interstitial fibrosis and inflammation) and partially/fully reversed CKD-associated urinary metabolite abnormalities; the EA extract showed the strongest nephroprotective effect among the three.

    • Overall: supportive preclinical evidence and mechanistic plausibility; human efficacy is suggested in reviews but not demonstrated with controlled clinical trial details in the provided abstracts.

  • Diabetic nephropathy: The DN abstract reports rhubarb “exhibited efficacy” in patients (reduced proteinuria, lowered blood sugar, improved kidney function), but provides no study design, sample size, controls, or quantitative results. The remainder is network pharmacology/docking identifying candidate compounds (rhein, beta-sitosterol, aloe-emodin) and targets/pathways (e.g., PI3K-Akt, p53, AGE-RAGE, MAPK), which is not clinical proof of benefit.

  • CIRI/stroke model (rat MCAO): In rats, rhubarb extract improved multiple outcomes versus model controls: increased gut microbial α-diversity, reduced Enterobacteriaceae, improved intestinal barrier markers (ZO-1, Occludin, Claudin 1), lowered serum LPS and D-lactate, reduced systemic inflammatory cytokines (including IL-1β, IL-6, TNF-α among others), improved blood-brain barrier integrity (reduced Evans blue penetration; improved tight junction protein expression), downregulated TLR4/MyD88/NF-κB signaling, and reduced neurological deficit scores and infarct volume. This is strong preclinical evidence; it does not establish efficacy in humans.

  • Menopausal symptoms: The women’s health botanical review lists Rheum rhaponticum among estrogenic botanicals used for menopausal symptom relief, but the abstract does not provide trial-level efficacy data or outcomes for rhubarb specifically.

  • Hepatocellular carcinoma (aloe-emodin): The aloe-emodin abstract describes network pharmacology/docking plus in vitro experiments to evaluate therapeutic effects/mechanisms in HCC. Because the results section is truncated, the provided text does not allow a clear conclusion on magnitude of anti-cancer effects.

3. What health benefits does it have?

  • Potential gastrointestinal benefit (constipation/IBS context): Rhubarb is discussed among functional foods considered for IBS and functional constipation management, consistent with its known purgative/laxative tradition (the abstract frames it as part of dietary strategies, but does not quantify benefit).

  • Kidney-related benefits (preclinical + traditional use):

    • Nephroprotective themes in CKD: anti-fibrotic, anti-oxidative, anti-inflammatory, and effects on autophagy/apoptosis are highlighted in the CKD review.

    • In CKD rats, rhubarb extracts improved renal function, reduced interstitial fibrosis/inflammation, and shifted disturbed metabolism (amino acid, purine, taurine, choline pathways) toward normal; ethyl acetate extract appeared most effective among tested fractions.

  • Neurovascular/brain protection via gut-brain axis (animal data): In CIRI rats, rhubarb extract improved intestinal barrier integrity, reduced endotoxemia markers (LPS, D-lactate), reduced systemic and hippocampal inflammatory cytokines, improved BBB integrity, and improved neurological outcomes (lower deficit scores and infarct volume).

  • Bioactive constituents with plausible mechanistic benefits:

    • Anthraquinones such as emodin and aloe-emodin are identified as rhubarb-derived compounds; aloe-emodin is described as anti-inflammatory and having antitumor activity (mechanisms under investigation).

    • Rhubarb is noted as a dietary source of resveratrol; the resveratrol abstract attributes anti-inflammatory and neuroprotective effects to resveratrol generally, though this does not prove rhubarb intake delivers clinically meaningful resveratrol exposure.

  • Potential menopausal symptom support (species-specific): Rheum rhaponticum is listed among botanicals with estrogenic activities used for menopausal symptom relief; the abstract does not provide rhubarb-specific efficacy outcomes.

4. Does it have any downsides or side effects?

  • Potential nephrotoxicity with inappropriate long-term use: The CKD review explicitly warns that “long-term inappropriate use” of rhubarb may damage renal function, despite nephroprotective effects in other contexts. This indicates a narrow safety margin depending on dose, duration, preparation, and patient factors.

  • General supplement safety limitations and interaction risk: The women’s health botanical review emphasizes that botanicals are often perceived as safe but “have not been rigorously tested” for toxic effects and/or drug–botanical interactions. This caution applies to rhubarb-containing products used for menopausal symptoms and potentially other indications.

  • Likely GI adverse effects (inferred from “purgative properties,” not quantified here): The CIRI abstract describes rhubarb as “known for its purgative properties,” which commonly implies diarrhea/abdominal cramping risk; however, the provided abstracts do not report adverse event rates or tolerability data.

  • Evidence gaps: Across indications, many findings are preclinical (rat models, metabolomics, docking) or review statements without detailed clinical trial reporting in the abstracts provided, limiting confidence about real-world benefit-risk balance.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., genotype-stratified efficacy/toxicity, metabolizer status, or specific gene variants predicting response) for rhubarb or its key constituents (rhein, emodin, aloe-emodin) in humans.

  • What is mentioned (not pharmacogenomics): The DN network pharmacology abstract identifies molecular targets/pathways (e.g., TP53, CASP3/8, PTGS2; PI3K-Akt, p53, AGE-RAGE, MAPK) and docking interactions (e.g., aloe-emodin with TP53). These are mechanistic hypotheses and do not establish that inherited variants in these genes change clinical response or risk.

  • Practical implication: Based on these abstracts alone, no evidence-based recommendations can be made to use or avoid rhubarb due to specific genetic variants.

References

  1. The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation.
    Prashant Singh, Caroline Tuck, Peter R Gibson, William D Chey (2022) - The American journal of gastroenterology
  2. Nephroprotective and nephrotoxic effects of Rhubarb and their molecular mechanisms.
    Fang Zhang, Rui Wu, Yanfang Liu, Shu Dai, Xinyan Xue, Yunxia Li, Xiaohong Gong (2023) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. Neuroprotection of rhubarb extract against cerebral ischaemia-reperfusion injury via the gut-brain axis pathway.
    Mingjiang Mao, Xingqin Cao, Yuhua Liang, Qiuying Li, Simiao Chen, Liping Zhou, Yuyan Zhang, Ying Guo (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.
    Stephanie Andrade, Maria João Ramalho, Maria do Carmo Pereira, Joana A Loureiro (2018) - Frontiers in pharmacology
  5. Botanicals and Their Bioactive Phytochemicals for Women's Health.
    Birgit M Dietz, Atieh Hajirahimkhan, Tareisha L Dunlap, Judy L Bolton (2016) - Pharmacological reviews
  6. The Health Benefits of Emodin, a Natural Anthraquinone Derived from Rhubarb-A Summary Update.
    Monika Stompor-Gorący (2021) - International journal of molecular sciences
  7. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis.
    Zhi-Hao Zhang, Feng Wei, Nosratola D Vaziri, Xian-Long Cheng, Xu Bai, Rui-Chao Lin, Ying-Yong Zhao (2015) - Scientific reports
  8. Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy.
    Shaojie Fu, Yena Zhou, Cong Hu, Zhonggao Xu, Jie Hou (2022) - BMC complementary medicine and therapies
  9. Exploring the mechanism of aloe-emodin in the treatment of liver cancer through network pharmacology and cell experiments
    Mingyang Zhu, Qingmin He, Yanan Wang, Liying Duan, Kang Rong (2023)
  10. Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome
    Leilei Zhai, Weiming Yang, Dianrong Li, Wei Zhou, Min Cui (2023)
  11. Rhubarb extract relieves constipation by stimulating mucus production in the colon and altering the intestinal flora.
    Chen-Chen Gao, Guang-Wen Li, Tian-Tian Wang, Lei Gao, Fei-Fei Wang, Hong-Wei Shang, Ze-Jun Yang, Yue-Xin Guo, Bo-Ya Wang, Jing-Dong Xu (2021) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. Advances in the study of emodin: an update on pharmacological properties and mechanistic basis.
    Qi Zheng, Shuo Li, Xiaojiaoyang Li, Runping Liu (2021) - Chinese medicine
  13. Hepatoprotection and hepatotoxicity of Chinese herb Rhubarb (Dahuang): How to properly control the "General (Jiang Jun)" in Chinese medical herb.
    Tongxi Zhuang, Xinyi Gu, Nian Zhou, Lili Ding, Li Yang, Mingmei Zhou (2020) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  14. Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound.
    Jiamei Le, Houlin Ji, Xiaoxiao Zhou, Xindong Wei, Yifan Chen, Yi Fu, Yujie Ma, Qiuqin Han, Yongning Sun, Yueqiu Gao, Hailong Wu (2021) - Frontiers in pharmacology
  15. Adverse Effects of Kampo Medicines.
    Yutaka Shimada (2022) - Internal medicine (Tokyo, Japan)
  16. Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials.
    Noah M A d'Unienville, Henry T Blake, Alison M Coates, Alison M Hill, Maximillian J Nelson, Jonathan D Buckley (2021) - Journal of the International Society of Sports Nutrition
  17. Neuroprotective Effects of Anthraquinones from Rhubarb in Central Nervous System Diseases.
    Xun Li, Shifeng Chu, Yinjiao Liu, Naihong Chen (2019) - Evidence-based complementary and alternative medicine : eCAM
  18. Constipation and Botanical Medicines: An Overview.
    Carla Cirillo, Raffaele Capasso (2015) - Phytotherapy research : PTR
  19. Update on Pharmacological Activities, Security, and Pharmacokinetics of Rhein.
    Gang-Min Li, Jun-Ren Chen, Hui-Qiong Zhang, Xiao-Yu Cao, Chen Sun, Fu Peng, Yan-Peng Yin, Ziwei Lin, Lei Yu, Yan Chen, Yun-Li Tang, Xiao-Fang Xie, Cheng Peng (2021) - Evidence-based complementary and alternative medicine : eCAM
  20. The phytochemistry and pharmacology of three Rheum species: A comprehensive review with future perspectives.
    Xiaorong Yang, Lixia Dai, Fengyuan Yan, Yudong Ma, Xiao Guo, Janar Jenis, Yu Wang, Jiyu Zhang, Xiaolou Miao, Xiaofei Shang (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!